NYSE · BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

$61.71

Down-$1.31 (-2.08%)

Updated Nov 4, 2026, 7:40 AM

SID Score

6.3/10

Composite research score

Smart Money

50/100

Neutral

Market cap: 104.23B
P/E ratio: 17.28
Dividend yield: 4.02%
52-week range: $53.44 – $68.64
Volume: 10.29M
Avg. volume: 16.54M

Price performance · BMY

BMY price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

Market data is busy. Please try again shortly.

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

institutionalNov 2, 2026

PZENA INVESTMENT MANAGEMENT LLC Reduces Holdings in Bristol-Myers Squibb Company (BMY)

earningsOct 29, 2026

Bristol-Myers Squibb (BMY) Beats Q3 Earnings Estimates by $0.11

analystOct 27, 2026

Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company (BMY)

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

BMY research

SID Coverage

Smart Investors Daily research and editorial coverage.

PZENA INVESTMENT MANAGEMENT LLC Reduces Holdings in Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) Beats Q3 Earnings Estimates by $0.11

Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company (BMY)

Featured By

PZENA INVESTMENT MANAGEMENT LLC Reduces Holdings in Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) Beats Q3 Earnings Estimates by $0.11

Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company (BMY)

Wells Fargo Reiterates Equal-Weight Rating on Bristol-Myers Squibb Company (BMY)

Daily Market Recap: Nvidia Soars, India IPO Boom and Fed Signals

Artemis Investment Management LLP Initiates New Position in Bristol-Myers Squibb Company (BMY)

Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Company (BMY)

BMY (BMY) Goes Ex-Dividend Tomorrow

Morgan Stanley Reiterates Underweight Rating on Bristol-Myers Squibb Company (BMY)

STATE STREET CORP Initiates New Position in Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) Downgraded to Market Perform by Leerink Partners

NORGES BANK Initiates New Position in Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) Upgraded to Buy at Argus Research

Bristol-Myers Squibb Company (BMY) Hits New 52-Week High of $65.14

Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Company (BMY)

Truist Securities Reiterates Buy Rating on Bristol-Myers Squibb Company (BMY)

Wells Fargo Reiterates Equal-Weight Rating on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) Beats Q2 Earnings Estimates by $0.43

Sumitomo Mitsui Trust Group, Inc. Increases Stake in Bristol-Myers Squibb Company (BMY) by 12.1%

Bristol-Myers Squibb Company (BMY) Hits New 52-Week High of $63.68

PZENA INVESTMENT MANAGEMENT LLC Reduces Holdings in Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) Beats Q3 Earnings Estimates by $0.11

Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company (BMY)